Data Take: Forget Teva and Mylan - Big Pharma Owns Generics

The pool at the foot of the patent cliff is a dark, dynamic vortex. Teva's imminent acquisition of Allergan's generics division just about moves the needle: but it's big pharma that dominates the off-patent drugs business these days.

production line

Only four of the top ten companies that compete in the generic drugs market – Teva Pharmaceutical Industries Ltd.,Fresenius Kabi AG, Mylan NV and Sun Pharmaceutical Industries Ltd. - are "generics" companies. The premier league includes six "originators" for whom off patent drugs just happen to account for 31-68% of their drug sales - Pfizer Inc., AstraZeneca PLC, Sanofi, Novartis AG, Novo Nordisk AS, and Otsuka Pharmaceutical Co. Ltd. (The main table at the end of the article shows the top 30 companies competing in the generics space).

At least since 2011, a time when the world's biggest ever selling drug, Pfizer's Lipitor, lost a large part of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.